# Multiple myeloma

Source: https://onco.cc/cancers/multiple-myeloma/  
OnCo record `multiple-myeloma` (Cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC.

## Summary

Multiple myeloma is a cancer of antibody-producing plasma cells in the bone marrow, causing anaemia, bone destruction, kidney failure and infections. It is preceded by MGUS and smouldering myeloma, which are common (MGUS in ~3% of people over 50) and mostly harmless; whether to treat high-risk smouldering disease (AQUILA, daratumumab) is a live debate, and Iceland is screening its whole adult population (iStopMM). Staging (R-ISS/R2-ISS) and cytogenetics (del17p, t(4;14), 1q gain) drive prognosis; MRD negativity at one in a million marrow cells has become both the best prognostic marker and, since 2024, an accepted regulatory endpoint.

No cancer has gained more drug classes: proteasome inhibitors (bortezomib 2003, carfilzomib), immunomodulatory cereblon modulators (thalidomide, lenalidomide, pomalidomide; next-generation CELMoDs iberdomide and mezigdomide), CD38 antibodies (daratumumab, isatuximab), BCMA-directed CAR-T (ide-cel, cilta-cel; anito-cel decision December 2026), BCMA and GPRC5D bispecific T-cell engagers (teclistamab, elranatamab, linvoseltamab, talquetamab), a BCMA ADC (belantamab, withdrawn 2022 and re-approved 2025), plus XPO1 and BCL-2 inhibitors for subsets. Newly diagnosed patients receive a quadruplet (Dara-VRd or Isa-VRd) whether or not they proceed to autologous transplant (PERSEUS, CEPHEUS, IMROZ), then lenalidomide maintenance; median survival in fit patients now exceeds ten years. At relapse, cilta-cel (CARTITUDE-4, OS HR 0.55) and teclistamab plus daratumumab (MajesTEC-3, approved March 2026) are second-line options, with sequencing by prior antigen exposure.

The frontier is replacing transplant and indefinite maintenance with a single CAR-T infusion (CARTITUDE-5/6), MRD-guided stopping of therapy, trispecifics and combinations that pre-empt antigen escape, and CELMoDs that restore sensitivity after lenalidomide. The hard problems are high-risk cytogenetics and extramedullary disease, which respond briefly to everything; infections and prolonged cytopenias from T-cell redirection; delayed neurotoxicity after BCMA CAR-T; cost and manufacturing slots; and the fact that the disease still relapses in almost everyone eventually, so 'functional cure' remains a claim to be proven.

## Fields

- Kind: Cancer
- Last checked: 2026-09-07
- Tags: heme; spike
- Group: haematologic
- Burden: Multiple myeloma causes ~190,000 new cases a year worldwide, ~36,000 in the US, at a median age of 69. More new drug classes than any other cancer have pushed median survival to more than 10 years in transplant-eligible patients and ~5-7 years in older patients; ~120,000 deaths a year worldwide.
- Subtypes: Standard-risk vs high-risk cytogenetics (IMS 2024 definition); Transplant-eligible vs transplant-ineligible (fitness, not age alone); Extramedullary disease (soft-tissue plasmacytomas; harder to control, a focus of CAR-T and bispecific trials); Plasma cell leukaemia (≥5% circulating plasma cells); Light-chain only, IgA, IgG, non-secretory; Smouldering myeloma and MGUS (precursors); Triple-class refractory / penta-refractory; BCMA-exposed vs BCMA-naive at relapse
- Biomarkers: Cytogenetics (del17p, t(4;14), 1q gain); R-ISS; MRD (NGS/flow); BCMA/GPRC5D expression; Serum and urine M-protein, free light chains; R-ISS / R2-ISS (β2-microglobulin, albumin, LDH, FISH); FISH: del(17p), t(4;14), t(14;16), t(14;20), 1q gain/amp, del(1p); TP53 mutation; MRD by NGS (clonoSEQ) or next-generation flow at 10⁻⁵ to 10⁻⁶; PET-CT and whole-body MRI (IMWG imaging); BCMA and GPRC5D expression / TNFRSF17 loss at relapse; Renal function, calcium, haemoglobin (CRAB criteria); Soluble BCMA (research)

## Sections of this record

The page is a hub with ten sections in reading order; large sections have their own page. The same plan as JSON: https://onco.cc/api/v1/cancers/multiple-myeloma/sections.json

- Overview (on the hub): The TL;DR, the family this cancer belongs to, the organ, who gets it and what the state of the art is. https://onco.cc/cancers/multiple-myeloma/#overview [5 subtypes, 9 state-of-the-art points]
- What it is (on the hub): Anatomy, the subtypes and how they differ, how it is staged, and where advanced disease spreads. https://onco.cc/cancers/multiple-myeloma/#what-it-is [13 subtypes, 3 sites of spread]
- Finding it (on the hub): How it shows itself, how it is confirmed, what screening exists, and the biomarkers clinicians test for. https://onco.cc/cancers/multiple-myeloma/#finding-it [13 biomarkers, 6 prevalence rows]
- Treating it (on the hub): The standard of care by setting, the medicines, surgery and radiotherapy named in it, and the regimens behind them. https://onco.cc/cancers/multiple-myeloma/#treating-it [10 settings, 8 regimens, 7 decisions with options]
- Evidence (own page): Trials recruiting now, the landmark trials, the key papers and what they mean, the latest literature, and the milestones year by year. https://onco.cc/cancers/multiple-myeloma/evidence/ [162 trials, 11 key papers, 22 milestones]
- The science (own page): The molecular landscape: the targets and how often each appears, the pathways, the mechanics stages and the preclinical models. https://onco.cc/cancers/multiple-myeloma/science/ [125 targets, 3 pathways, 7 preclinical models]
- Where you are (own page): Cases by country, the UK and NHS pathway and other country lenses, and the expert centres with trials on record. https://onco.cc/cancers/multiple-myeloma/where-you-are/ [31 centres]
- Living with it (on the hub): The decisions you may face, the aids that walk through them, the warnings on record, the first sixty days and the questions to ask. https://onco.cc/cancers/multiple-myeloma/#living-with-it [31 questions, 6 red cards]
- What is coming (own page): Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record. https://onco.cc/cancers/multiple-myeloma/coming/ [58 medicines, 162 trials, 17 ideas, 11 open problems]
- Data (own page): Every connected record, the notes, the JSON, Markdown and RDF twins, and where the record came from and when it was checked. https://onco.cc/cancers/multiple-myeloma/data/ [600 connected records]

## Standard of care

- Newly diagnosed: Dara-VRd ± ASCT → lenalidomide maintenance. ([Whole-body MRI](https://onco.cc/technologies/whole-body-mri/))
- Relapsed: CAR-T or bispecific; belantamab combinations; sequencing by prior exposure. ([Ciltacabtagene autoleucel](https://onco.cc/drugs/ciltacabtagene-autoleucel/), [Teclistamab](https://onco.cc/drugs/teclistamab/), [Belantamab mafodotin](https://onco.cc/drugs/belantamab-mafodotin/))
- MGUS / low-risk smouldering: Observation with periodic labs; no treatment outside trials. ([Smouldering myeloma / MGUS](https://onco.cc/terms/smoldering-myeloma/), [iStopMM](https://onco.cc/trials/istopmm/))
- High-risk smouldering myeloma: Consider daratumumab monotherapy (AQUILA) or lenalidomide (E3A06), or trial enrolment; shared decision given indolent course in many. ([Daratumumab](https://onco.cc/drugs/daratumumab/), [Lenalidomide](https://onco.cc/drugs/lenalidomide/), [Smouldering myeloma / MGUS](https://onco.cc/terms/smoldering-myeloma/))
- Newly diagnosed, transplant-eligible: Dara-VRd (or Isa-VRd) induction × 4-6 → stem-cell collection → high-dose melphalan + autologous transplant → Dara-VRd consolidation → lenalidomide (± daratumumab) maintenance; MRD-guided de-escalation emerging (PERSEUS design). Tandem transplant or extended therapy for high risk. ([PERSEUS](https://onco.cc/trials/perseus/), [Daratumumab](https://onco.cc/drugs/daratumumab/), [Bortezomib](https://onco.cc/drugs/bortezomib/), [Lenalidomide](https://onco.cc/drugs/lenalidomide/), [Autologous stem cell transplant (high-dose therapy)](https://onco.cc/technologies/autologous-stem-cell-transplant/), [MRD negativity (myeloma, 10⁻⁵ / 10⁻⁶)](https://onco.cc/terms/mrd-negativity-myeloma/))
- Newly diagnosed, transplant-ineligible: Dara-VRd (CEPHEUS) or Isa-VRd (IMROZ) with bortezomib de-escalation after induction; Dara-Rd (MAIA) for frailer patients; continuous therapy with dose adjustment for frailty. ([CEPHEUS](https://onco.cc/trials/cepheus/), [IMROZ](https://onco.cc/trials/imroz/), [Daratumumab](https://onco.cc/drugs/daratumumab/), [Isatuximab](https://onco.cc/drugs/isatuximab/), [Lenalidomide](https://onco.cc/drugs/lenalidomide/))
- Maintenance: Lenalidomide until progression (CALGB 100104, Myeloma XI); daratumumab added for high-risk or per PERSEUS; MRD-guided discontinuation in trials (DRAMMATIC, MASTER); iberdomide maintenance (EXCALIBER) pending. ([Lenalidomide](https://onco.cc/drugs/lenalidomide/), [Daratumumab](https://onco.cc/drugs/daratumumab/), [Iberdomide](https://onco.cc/drugs/iberdomide/), [MRD-guided treatment-free intervals in myeloma](https://onco.cc/ideas/idea-mrd-guided-stop-myeloma/), [DRAMMATIC](https://onco.cc/trials/drammatic/))
- First relapse (1-3 prior lines): Cilta-cel if lenalidomide-refractory (CARTITUDE-4); teclistamab + daratumumab (MajesTEC-3, 2026); ide-cel after ≥2 lines; belantamab-Vd or -Pd (DREAMM-7/8); CD38-based triplets (Dara-Kd, Isa-Kd, Dara-Pd) by prior exposure; carfilzomib or pomalidomide combinations. ([Ciltacabtagene autoleucel](https://onco.cc/drugs/ciltacabtagene-autoleucel/), [CARTITUDE-4](https://onco.cc/trials/cartitude-4/), [Teclistamab](https://onco.cc/drugs/teclistamab/), [MajesTEC-3](https://onco.cc/trials/majestec-3/), [Idecabtagene vicleucel](https://onco.cc/drugs/idecabtagene-vicleucel/), [KarMMa-3](https://onco.cc/trials/karmma-3/), [Belantamab mafodotin](https://onco.cc/drugs/belantamab-mafodotin/), [DREAMM-7](https://onco.cc/trials/dreamm-7/), [DREAMM-8](https://onco.cc/trials/dreamm-8/), [Carfilzomib](https://onco.cc/drugs/carfilzomib/))
- Triple-class refractory (≥3-4 prior lines): BCMA CAR-T if not yet given; bispecifics (teclistamab, elranatamab, linvoseltamab; talquetamab after BCMA exposure); belantamab; selinexor-based; CELMoDs in trials; anito-cel (PDUFA Dec 2026). ([Teclistamab](https://onco.cc/drugs/teclistamab/), [Elranatamab](https://onco.cc/drugs/elranatamab/), [Linvoseltamab](https://onco.cc/drugs/linvoseltamab/), [Talquetamab](https://onco.cc/drugs/talquetamab/), [Belantamab mafodotin](https://onco.cc/drugs/belantamab-mafodotin/), [Mezigdomide](https://onco.cc/drugs/mezigdomide/), [Anitocabtagene autoleucel](https://onco.cc/drugs/anitocabtagene-autoleucel/), [BCMA-directed therapy → GPRC5D-directed therapy](https://onco.cc/pairings/bcma-then-gprc5d/))
- Supportive care: Bisphosphonate or denosumab for bone disease; IVIG, antiviral, PJP prophylaxis and vaccination during T-cell redirection; thromboprophylaxis with IMiDs; renal protection; radiotherapy for painful lesions or cord compression. ([Caution: T-cell redirectors and infections](https://onco.cc/pairings/bispecific-infection-prophylaxis/), [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/))

## State of the art

- CAR-T in second line.
- Bispecifics after one prior line (2026).
- Functional cure discussions.
- Quadruplet induction (CD38 antibody + PI + IMiD + dexamethasone) for all newly diagnosed patients, with MRD negativity in 60-75%.
- CAR-T with a survival benefit as early as second line (CARTITUDE-4, OS HR 0.55) and a third of late-line patients progression-free at five years without maintenance (CARTITUDE-1).
- Two antigens for T-cell redirection (BCMA, GPRC5D) with four approved bispecifics; teclistamab plus daratumumab approved at first relapse (March 2026).
- MRD negativity accepted by FDA as an endpoint for accelerated approval (2024), enabling faster trials and MRD-guided therapy.
- Belantamab returned after withdrawal on the strength of two positive phase 3s, a rare regulatory reversal.
- Nationwide precursor screening (iStopMM) and precursor treatment (AQUILA) are redefining where 'myeloma care' begins.

## Open problems

- High-risk cytogenetics.
- Infections with T-cell redirecting therapy.
- Cost and access.
- High-risk cytogenetics and extramedullary disease respond briefly to every class; no regimen closes the gap.
- Infections are the main safety problem on bispecifics; hypogammaglobulinaemia and T-cell exhaustion need better mitigation than IVIG and dose de-intensification.
- Delayed neurotoxicity (parkinsonism, cranial neuropathies) after BCMA CAR-T and second primary malignancies after cereblon modulators and CAR-T.
- Sequencing after BCMA failure: antigen loss (TNFRSF17 deletion) versus T-cell fitness; how to combine or alternate BCMA and GPRC5D agents.
- Is transplant still needed? CARTITUDE-6 will answer; until then most fit patients receive high-dose melphalan.
- Whether MRD-guided stopping is safe; whether MRD negativity at 10⁻⁶ equals cure for anyone.
- Precursor disease: treating high-risk smouldering myeloma prevents progression but may over-treat; population screening's mortality effect is unknown.
- Cost and capacity: CAR-T slots, bispecific hospitalisation for step-up dosing, and lifelong therapy costs strain every health system.

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Multiple_myeloma
- Wikipedia: https://en.wikipedia.org/wiki/Multiple_myeloma

## Connected records

- pairings: [BCMA-directed therapy → GPRC5D-directed therapy](https://onco.cc/pairings/bcma-then-gprc5d/), [Caution: T-cell redirectors and infections](https://onco.cc/pairings/bispecific-infection-prophylaxis/), [CD38 antibody added to PI-IMiD-dex (quadruplet induction)](https://onco.cc/pairings/cd38-plus-triplet/)
- collections: [Leukemia & Lymphoma Society (LLS)](https://onco.cc/collections/leukemia-lymphoma-society/), [Multiple Myeloma Research Foundation (MMRF)](https://onco.cc/collections/mmrf/)
- technologies: [Allogeneic cell banks: one donor, hundreds of doses](https://onco.cc/technologies/allogeneic-cell-banks/), [Allogeneic stem cell transplantation](https://onco.cc/technologies/allogeneic-hsct/), [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Autologous CAR-T manufacturing, batch by batch](https://onco.cc/technologies/car-t-manufacturing-process/), [Autologous stem cell transplant (high-dose therapy)](https://onco.cc/technologies/autologous-stem-cell-transplant/), [Bone-modifying agents (bisphosphonates, denosumab)](https://onco.cc/technologies/bone-modifying-agents/), [Cancer-associated thrombosis prevention and treatment](https://onco.cc/technologies/cancer-associated-thrombosis/), [CAR-T cell therapy](https://onco.cc/technologies/car-t/), [Cereblon E3 ligase modulators (CELMoDs)](https://onco.cc/technologies/celmods/), [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Dual-energy and spectral CT](https://onco.cc/technologies/dual-energy-spectral-ct/), [Ex vivo drug sensitivity screening in blood cancers (EXALT)](https://onco.cc/technologies/functional-precision-medicine-haematology/), [FDG PET](https://onco.cc/technologies/fdg-pet/), [Flow cytometers](https://onco.cc/technologies/flow-cytometers/), [Gamma-secretase inhibitors](https://onco.cc/technologies/gamma-secretase-inhibitors/), [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/), [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/), [MRD / molecular residual disease testing](https://onco.cc/technologies/mrd-testing/), [MRI field strengths: 1.5 T, 3 T and 7 T](https://onco.cc/technologies/mri-field-strengths/), [Multiparameter flow cytometry MRD](https://onco.cc/technologies/flow-cytometry-mrd/), [NGS-based MRD (clonoSEQ and molecular MRD)](https://onco.cc/technologies/ngs-mrd-clonoseq/), [Palliative radiotherapy](https://onco.cc/technologies/palliative-radiotherapy/), [Photobiomodulation (low-level laser) for oral mucositis](https://onco.cc/technologies/photobiomodulation-mucositis/), [Photon-counting CT](https://onco.cc/technologies/photon-counting-ct/), [PROTACs & molecular glues (targeted protein degradation)](https://onco.cc/technologies/protac-degrader/), [Serum tumour markers: proper use and misuse](https://onco.cc/technologies/serum-tumour-markers/), [T-cell engagers (bispecific)](https://onco.cc/technologies/t-cell-engager/), [Trispecific antibodies](https://onco.cc/technologies/trispecific-antibodies/), [Whole-body MRI](https://onco.cc/technologies/whole-body-mri/), [X-ray radiography and fluoroscopy](https://onco.cc/technologies/x-ray-radiography-fluoroscopy/)
- targets: [ADAMTS9](https://onco.cc/targets/adamts9/), [ADRM1](https://onco.cc/targets/adrm1/), [ARHGAP5](https://onco.cc/targets/arhgap5/), [BCL7A](https://onco.cc/targets/bcl7a/), [BCMA](https://onco.cc/targets/bcma/), [BTG1](https://onco.cc/targets/btg1/), [CCND1](https://onco.cc/targets/ccnd1/), [CD3](https://onco.cc/targets/cd3/), [CD38](https://onco.cc/targets/cd38/), [CD3D](https://onco.cc/targets/cd3d/), [CD3G](https://onco.cc/targets/cd3g/), [CDKN1B](https://onco.cc/targets/cdkn1b/), [Cereblon (CRBN)](https://onco.cc/targets/cereblon/), [COL1A1](https://onco.cc/targets/col1a1/), [CTAG1B](https://onco.cc/targets/ctag1b/), [CTAG2](https://onco.cc/targets/ctag2/), [CUL4A](https://onco.cc/targets/cul4a/), [CXCR4](https://onco.cc/targets/cxcr4/), [CYLD](https://onco.cc/targets/cyld/), [DDB1](https://onco.cc/targets/ddb1/), [DIS3](https://onco.cc/targets/dis3/), [EFTUD2](https://onco.cc/targets/eftud2/), [Exportin-1 (XPO1)](https://onco.cc/targets/xpo1/), [FcRH5 (FCRL5)](https://onco.cc/targets/fcrh5/), [FDPS](https://onco.cc/targets/fdps/), [Glucocorticoid receptor (NR3C1)](https://onco.cc/targets/glucocorticoid-receptor/), [GPRC5D](https://onco.cc/targets/gprc5d/), [HDAC10](https://onco.cc/targets/hdac10/), [HDAC11](https://onco.cc/targets/hdac11/), [HDAC4](https://onco.cc/targets/hdac4/), [HDAC5](https://onco.cc/targets/hdac5/), [HDAC7](https://onco.cc/targets/hdac7/), [HDAC8](https://onco.cc/targets/hdac8/), [HDAC9](https://onco.cc/targets/hdac9/), [Histone deacetylases (HDAC)](https://onco.cc/targets/hdac/), [IFNAR2](https://onco.cc/targets/ifnar2/), [IKBKB](https://onco.cc/targets/ikbkb/), [IKZF1 (Ikaros)](https://onco.cc/targets/ikzf1/), [IKZF3 (Aiolos)](https://onco.cc/targets/ikzf3/), [Interleukin-6 and IL-6 receptor](https://onco.cc/targets/il6/), [IRAK1](https://onco.cc/targets/irak1/), [IRF1](https://onco.cc/targets/irf1/), [IRF4](https://onco.cc/targets/irf4/), [KDM5C](https://onco.cc/targets/kdm5c/), [MAF](https://onco.cc/targets/maf/), [MAX](https://onco.cc/targets/max/), [MCL1](https://onco.cc/targets/mcl1/), [MYC](https://onco.cc/targets/myc-gene/), [MYCL](https://onco.cc/targets/mycl/), [NFKBIA](https://onco.cc/targets/nfkbia/), [NSD2](https://onco.cc/targets/nsd2/), [PABPC1](https://onco.cc/targets/pabpc1/), [PARP4](https://onco.cc/targets/parp4/), [PIM1](https://onco.cc/targets/pim1/), [PRDM1](https://onco.cc/targets/prdm1/), [PRDM16](https://onco.cc/targets/prdm16/), [PRKD2](https://onco.cc/targets/prkd2/), [Proteasome (PSMB5)](https://onco.cc/targets/proteasome/), [PSMA1](https://onco.cc/targets/psma1/), [PSMA2](https://onco.cc/targets/psma2/), [PSMA3](https://onco.cc/targets/psma3/), [PSMA4](https://onco.cc/targets/psma4/), [PSMA5](https://onco.cc/targets/psma5/), [PSMA6](https://onco.cc/targets/psma6/), [PSMA7](https://onco.cc/targets/psma7/), [PSMA8](https://onco.cc/targets/psma8/), [PSMB1](https://onco.cc/targets/psmb1/), [PSMB10](https://onco.cc/targets/psmb10/), [PSMB11](https://onco.cc/targets/psmb11/), [PSMB2](https://onco.cc/targets/psmb2/), [PSMB3](https://onco.cc/targets/psmb3/), [PSMB4](https://onco.cc/targets/psmb4/), [PSMB6](https://onco.cc/targets/psmb6/), [PSMB7](https://onco.cc/targets/psmb7/), [PSMB8](https://onco.cc/targets/psmb8/), [PSMB9](https://onco.cc/targets/psmb9/), [PSMC1](https://onco.cc/targets/psmc1/), [PSMC2](https://onco.cc/targets/psmc2/), [PSMC3](https://onco.cc/targets/psmc3/), [PSMC4](https://onco.cc/targets/psmc4/), [PSMC5](https://onco.cc/targets/psmc5/), [PSMC6](https://onco.cc/targets/psmc6/), [PSMD1](https://onco.cc/targets/psmd1/), [PSMD11](https://onco.cc/targets/psmd11/), [PSMD12](https://onco.cc/targets/psmd12/), [PSMD13](https://onco.cc/targets/psmd13/), [PSMD14](https://onco.cc/targets/psmd14/), [PSMD2](https://onco.cc/targets/psmd2/), [PSMD3](https://onco.cc/targets/psmd3/), [PSMD4](https://onco.cc/targets/psmd4/), [PSMD6](https://onco.cc/targets/psmd6/), [PSMD7](https://onco.cc/targets/psmd7/), [PSMD8](https://onco.cc/targets/psmd8/), [RANK ligand (RANKL)](https://onco.cc/targets/rankl/), [RBX1](https://onco.cc/targets/rbx1/), [RPL10](https://onco.cc/targets/rpl10/), [RPS3A](https://onco.cc/targets/rps3a/), [SAMHD1](https://onco.cc/targets/samhd1/), [SEM1](https://onco.cc/targets/sem1/), [SLAMF7 (CS1)](https://onco.cc/targets/slamf7/), [SP140](https://onco.cc/targets/sp140/), [TENT5C](https://onco.cc/targets/tent5c/), [TNFRSF13B](https://onco.cc/targets/tnfrsf13b/), [TP53](https://onco.cc/targets/tp53/), [TRAF3](https://onco.cc/targets/traf3/), [TUBA1A](https://onco.cc/targets/tuba1a/), [TUBA1B](https://onco.cc/targets/tuba1b/), [TUBA1C](https://onco.cc/targets/tuba1c/), [TUBA3C](https://onco.cc/targets/tuba3c/), [TUBA3E](https://onco.cc/targets/tuba3e/), [TUBA4A](https://onco.cc/targets/tuba4a/), [TUBB1](https://onco.cc/targets/tubb1/), [TUBB2A](https://onco.cc/targets/tubb2a/), [TUBB2B](https://onco.cc/targets/tubb2b/), [TUBB3](https://onco.cc/targets/tubb3/), [TUBB4A](https://onco.cc/targets/tubb4a/), [TUBB4B](https://onco.cc/targets/tubb4b/), [TUBB6](https://onco.cc/targets/tubb6/), [TUBB8](https://onco.cc/targets/tubb8/), [USP7](https://onco.cc/targets/usp7/), [USP8](https://onco.cc/targets/usp8/), [ZEB1](https://onco.cc/targets/zeb1/), [ZFHX3](https://onco.cc/targets/zfhx3/)
- drugs: [5-Aminolevulinic acid (oral, for glioma surgery)](https://onco.cc/drugs/aminolevulinic-acid-gleolan/), [Anitocabtagene autoleucel](https://onco.cc/drugs/anitocabtagene-autoleucel/), [Arlocabtagene Autoleucel](https://onco.cc/drugs/arlocabtagene-autoleucel/), [AZD0120](https://onco.cc/drugs/azd0120/), [AZD4045](https://onco.cc/drugs/azd4045/), [Belantamab mafodotin](https://onco.cc/drugs/belantamab-mafodotin/), [Bortezomib](https://onco.cc/drugs/bortezomib/), [Carfilzomib](https://onco.cc/drugs/carfilzomib/), [Carmustine](https://onco.cc/drugs/carmustine/), [Cevostamab](https://onco.cc/drugs/cevostamab/), [Ciltacabtagene autoleucel](https://onco.cc/drugs/ciltacabtagene-autoleucel/), [clonoSEQ](https://onco.cc/drugs/clonoseq/), [Cyclophosphamide](https://onco.cc/drugs/cyclophosphamide/), [Daratumumab](https://onco.cc/drugs/daratumumab/), [Denosumab](https://onco.cc/drugs/denosumab/), [Dexamethasone](https://onco.cc/drugs/dexamethasone/), [Elotuzumab](https://onco.cc/drugs/elotuzumab/), [Elranatamab](https://onco.cc/drugs/elranatamab/), [Equecabtagene autoleucel](https://onco.cc/drugs/equecabtagene-autoleucel/), [F182112](https://onco.cc/drugs/f182112/), [Feladilimab](https://onco.cc/drugs/feladilimab/), [Fluciclovine F-18](https://onco.cc/drugs/fluciclovine-f18/), [GC012F](https://onco.cc/drugs/gc012f/), [GR1803](https://onco.cc/drugs/gr1803/), [Human normal immunoglobulin (IVIg)](https://onco.cc/drugs/human-normal-immunoglobulin/), [Iberdomide](https://onco.cc/drugs/iberdomide/), [Idecabtagene vicleucel](https://onco.cc/drugs/idecabtagene-vicleucel/), [Isatuximab](https://onco.cc/drugs/isatuximab/), [ISB 2001](https://onco.cc/drugs/isb-2001/), [Ixazomib](https://onco.cc/drugs/ixazomib/), [JNJ-79635322](https://onco.cc/drugs/jnj-79635322/), [Lenalidomide](https://onco.cc/drugs/lenalidomide/), [Linvoseltamab](https://onco.cc/drugs/linvoseltamab/), [Melphalan (including hepatic delivery system)](https://onco.cc/drugs/melphalan/), [Melphalan flufenamide](https://onco.cc/drugs/melflufen/), [Mezigdomide](https://onco.cc/drugs/mezigdomide/), [Motixafortide](https://onco.cc/drugs/motixafortide/), [NXC-201 CAR-T](https://onco.cc/drugs/nxc-201-car-t/), [Palifermin](https://onco.cc/drugs/palifermin/), [Pamidronate](https://onco.cc/drugs/pamidronate/), [Panobinostat](https://onco.cc/drugs/panobinostat/), [Pegulicianine](https://onco.cc/drugs/pegulicianine/), [Pegylated liposomal doxorubicin](https://onco.cc/drugs/pegylated-liposomal-doxorubicin/), [Plerixafor](https://onco.cc/drugs/plerixafor/), [Plitidepsin](https://onco.cc/drugs/plitidepsin/), [Pomalidomide](https://onco.cc/drugs/pomalidomide/), [Purinostat](https://onco.cc/drugs/purinostat/), [QLS32015](https://onco.cc/drugs/qls32015/), [SCTC21C](https://onco.cc/drugs/sctc21c/), [Selinexor](https://onco.cc/drugs/selinexor/), [SG301](https://onco.cc/drugs/sg301/), [Sipuleucel-T](https://onco.cc/drugs/sipuleucel-t/), [STI-6129](https://onco.cc/drugs/sti-6129/), [Talquetamab](https://onco.cc/drugs/talquetamab/), [Teclistamab](https://onco.cc/drugs/teclistamab/), [Thalidomide](https://onco.cc/drugs/thalidomide/), [Zevorcabtagene autoleucel](https://onco.cc/drugs/zevorcabtagene-autoleucel/), [Zoledronic acid](https://onco.cc/drugs/zoledronic-acid/)
- companies: [Active Biotech](https://onco.cc/companies/active-biotech/), [Adaptive Biotechnologies](https://onco.cc/companies/adaptive-biotechnologies/), [Aeterna Zentaris](https://onco.cc/companies/aeterna-zentaris/), [Amgen](https://onco.cc/companies/amgen/), [Angiocrine Bioscience](https://onco.cc/companies/angiocrine-bioscience/), [Antengene](https://onco.cc/companies/antengene/), [Arcellx](https://onco.cc/companies/arcellx/), [Aurigene Oncology](https://onco.cc/companies/aurigene/), [BioLineRx](https://onco.cc/companies/biolinerx/), [Bristol Myers Squibb](https://onco.cc/companies/bms/), [C4 Therapeutics](https://onco.cc/companies/c4-therapeutics/), [Cartesian Therapeutics](https://onco.cc/companies/cartesian-therapeutics/), [Cellectar Biosciences](https://onco.cc/companies/cellectar/), [Celltrion](https://onco.cc/companies/celltrion/), [Chongqing Precision Biotech](https://onco.cc/companies/chongqing-precision-biotech/), [European Myeloma Network](https://onco.cc/companies/european-myeloma-network/), [Foghorn Therapeutics](https://onco.cc/companies/foghorn-therapeutics/), [Genmab](https://onco.cc/companies/genmab/), [Gilead Sciences (incl. Kite)](https://onco.cc/companies/gilead/), [GIMEMA](https://onco.cc/companies/gimema/), [Glenmark Pharmaceuticals (Ichnos Glenmark Innovation)](https://onco.cc/companies/glenmark/), [GSK](https://onco.cc/companies/gsk/), [Hangzhou Sumgen Biotech](https://onco.cc/companies/hangzhou-sumgen-biotech/), [Heidelberg Pharma](https://onco.cc/companies/heidelberg-pharma/), [HOVON](https://onco.cc/companies/hovon/), [Indapta Therapeutics](https://onco.cc/companies/indapta-therapeutics/), [Intergroupe Francophone du Myélome (IFM)](https://onco.cc/companies/ifm/), [Johnson & Johnson](https://onco.cc/companies/johnson-johnson/), [JW Pharmaceutical](https://onco.cc/companies/jw-pharmaceutical/), [K36 Therapeutics](https://onco.cc/companies/k36-therapeutics/), [Kelonia Therapeutics](https://onco.cc/companies/kelonia-therapeutics/), [Legend Biotech](https://onco.cc/companies/legend-biotech/), [Leukemia & Lymphoma Society Therapy Acceleration Program](https://onco.cc/companies/lls-therapy-acceleration-program/), [Mission Bio](https://onco.cc/companies/mission-bio/), [Multiple Myeloma Research Foundation and Myeloma Investment Fund](https://onco.cc/companies/mmrf-myeloma-investment-fund/), [Nanjing Leads Biolabs](https://onco.cc/companies/nanjing-leads-biolabs/), [Oncopeptides](https://onco.cc/companies/oncopeptides/), [Orna Therapeutics (Eli Lilly)](https://onco.cc/companies/orna-therapeutics/), [Outcomes4Me](https://onco.cc/companies/outcomes4me/), [Pfizer (incl. Seagen)](https://onco.cc/companies/pfizer/), [Poseida Therapeutics](https://onco.cc/companies/poseida-therapeutics/), [Qilu Pharmaceutical](https://onco.cc/companies/qilu-pharmaceutical/), [Regeneron](https://onco.cc/companies/regeneron/), [Sanofi](https://onco.cc/companies/sanofi/), [Shanghai AbelZeta](https://onco.cc/companies/shanghai-abelzeta/), [Sinocelltech](https://onco.cc/companies/sinocelltech/), [SonALAsense](https://onco.cc/companies/sonalasense/), [Sorrento Therapeutics](https://onco.cc/companies/sorrento-therapeutics/), [Takeda](https://onco.cc/companies/takeda/)
- institutions: [American Society of Hematology](https://onco.cc/institutions/ash/), [Cancer Center Clínica Universidad de Navarra / CIMA](https://onco.cc/institutions/cun-navarra/), [Cancer Institute AP-HP Nord, Université Paris Cité](https://onco.cc/institutions/aphp-nord-cancer-institute/), [Christian Medical College, Vellore](https://onco.cc/institutions/cmc-vellore/), [Comprehensive Cancer Center Mainfranken, University Hospital Würzburg](https://onco.cc/institutions/ccc-wuerzburg/), [Dana-Farber Brigham Cancer Center](https://onco.cc/institutions/dana-farber/), [European Hematology Association](https://onco.cc/institutions/eha/), [Hadassah Medical Center](https://onco.cc/institutions/hadassah/), [Hospital Clínic de Barcelona / IDIBAPS](https://onco.cc/institutions/hospital-clinic-barcelona/), [Hospital Universitario 12 de Octubre](https://onco.cc/institutions/12-de-octubre/), [IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico Sant'Orsola](https://onco.cc/institutions/sant-orsola-bologna/), [IUCT Oncopole (Institut Universitaire du Cancer de Toulouse)](https://onco.cc/institutions/iuct-oncopole/), [Leeds Cancer Centre, St James's University Hospital](https://onco.cc/institutions/leeds-cancer-centre/), [Lille University Hospital (CHU de Lille)](https://onco.cc/institutions/chu-lille/), [Mayo Clinic](https://onco.cc/institutions/mayo-clinic/), [Mayo Clinic Comprehensive Cancer Center in Arizona](https://onco.cc/institutions/mayo-clinic-arizona/), [MD Anderson Cancer Center](https://onco.cc/institutions/md-anderson/), [Memorial Sloan Kettering Cancer Center](https://onco.cc/institutions/mskcc/), [Nantes University Hospital (CHU de Nantes)](https://onco.cc/institutions/chu-nantes/), [National and Kapodistrian University of Athens, School of Medicine](https://onco.cc/institutions/nkua-athens/), [Rambam Health Care Campus](https://onco.cc/institutions/rambam/), [Seoul St. Mary's Hospital](https://onco.cc/institutions/seoul-st-marys-hospital/), [Sylvester Comprehensive Cancer Center, University of Miami](https://onco.cc/institutions/sylvester-miami/), [Tennessee Oncology / Greco-Hainsworth Centers for Research](https://onco.cc/institutions/tennessee-oncology/), [The Mount Sinai Hospital / Tisch Cancer Institute](https://onco.cc/institutions/mount-sinai/), [The University of Kansas Cancer Center](https://onco.cc/institutions/ku-cancer-center/), [Union Hospital, Tongji Medical College](https://onco.cc/institutions/union-hospital-wuhan/), [University Hospital of Salamanca / IBSAL](https://onco.cc/institutions/hospital-universitario-salamanca/), [University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center](https://onco.cc/institutions/maryland-greenebaum/), [VCU Massey Comprehensive Cancer Center](https://onco.cc/institutions/vcu-massey/), [Winship Cancer Institute of Emory University](https://onco.cc/institutions/emory-winship/)
- terms: [Autologous stem cell transplant (ASCT)](https://onco.cc/terms/autologous-transplant/), [B cell](https://onco.cc/terms/b-cell/), [Bone metastases and skeletal-related events](https://onco.cc/terms/bone-metastases/), [Cancer health disparities and equity](https://onco.cc/terms/cancer-health-disparities/), [Cytogenetics and karyotype](https://onco.cc/terms/cytogenetics/), [Cytokine release syndrome (CRS)](https://onco.cc/terms/crs/), [Fixed-duration vs continuous therapy](https://onco.cc/terms/fixed-duration/), [Flow cytometry (immunophenotyping)](https://onco.cc/terms/flow-cytometry/), [High-risk cytogenetics (myeloma)](https://onco.cc/terms/high-risk-myeloma/), [ICANS (neurotoxicity)](https://onco.cc/terms/icans/), [Immunomodulatory drugs (IMiDs) and CELMoDs](https://onco.cc/terms/imid/), [Induction therapy](https://onco.cc/terms/induction-therapy/), [Leukaemia (tissue type)](https://onco.cc/terms/leukaemia-type/), [Maintenance therapy](https://onco.cc/terms/maintenance-therapy/), [Minimal / molecular residual disease (MRD)](https://onco.cc/terms/mrd/), [MRD negativity (myeloma, 10⁻⁵ / 10⁻⁶)](https://onco.cc/terms/mrd-negativity-myeloma/), [MRD-negative complete remission](https://onco.cc/terms/mrd-negative-cr/), [Obesity-related cancers (IARC list of 13)](https://onco.cc/terms/obesity-related-cancers/), [Proteasome inhibitor (bortezomib, carfilzomib, ixazomib)](https://onco.cc/terms/proteasome-inhibitor/), [R-ISS / R2-ISS staging](https://onco.cc/terms/r-iss/), [Smouldering myeloma / MGUS](https://onco.cc/terms/smoldering-myeloma/), [Undetectable MRD (uMRD / MRD-negative)](https://onco.cc/terms/umrd/), [VRd and Dara-VRd (myeloma induction regimens)](https://onco.cc/terms/vrd/)
- trials: [a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease](https://onco.cc/trials/nct04776330/), [A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients](https://onco.cc/trials/nct06508983/), [A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma](https://onco.cc/trials/nct06049290/), [A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma](https://onco.cc/trials/nct07681596/), [A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma](https://onco.cc/trials/nct07579234/), [A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)](https://onco.cc/trials/nct04988555/), [A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies](https://onco.cc/trials/nct05908409/), [A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Darat](https://onco.cc/trials/nct04973605/), [A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)](https://onco.cc/trials/nct06464991/), [A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Pl](https://onco.cc/trials/nct03246529/), [A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With H](https://onco.cc/trials/nct06140524/), [A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult Participants With Smoldering Multiple Myeloma at High Risk of Deve](https://onco.cc/trials/nct05955508/), [A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma](https://onco.cc/trials/nct06413498/), [A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Rela](https://onco.cc/trials/nct07391657/), [A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma](https://onco.cc/trials/nct07258511/), [A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma](https://onco.cc/trials/nct07518186/), [A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma](https://onco.cc/trials/nct07138209/), [A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination Wi](https://onco.cc/trials/nct05455320/), [A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortez](https://onco.cc/trials/nct06208150/), [A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With](https://onco.cc/trials/nct05572515/), [A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) ](https://onco.cc/trials/nct03539744/), [A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multi](https://onco.cc/trials/nct05535244/), [A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relaps](https://onco.cc/trials/nct07589634/), [A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma](https://onco.cc/trials/nct05583617/), [A Study of Aplidin (Plitidepsin) 3 h iv in Subjects With Relapsing or Refractory Multiple Myeloma](https://onco.cc/trials/nct00229203/), [A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethas](https://onco.cc/trials/nct06679101/), [A Study of C-CAR088 in Patients With Relapsed or Refractory Multiple Myeloma](https://onco.cc/trials/nct05521802/), [A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma](https://onco.cc/trials/nct06550895/), [A Study of CM336 in Patients With Relapsed or Refractory Multiple Myeloma](https://onco.cc/trials/nct05299424/), [A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractor](https://onco.cc/trials/nct03314181/), [A Study of Daratumumab](https://onco.cc/trials/nct05438043/), [A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Ind](https://onco.cc/trials/nct06577025/), [A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma](https://onco.cc/trials/nct07312188/), [A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma](https://onco.cc/trials/nct06980480/), [A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma](https://onco.cc/trials/nct06235229/), [A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma](https://onco.cc/trials/nct07452198/), [A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma](https://onco.cc/trials/nct06083207/), [A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Mul](https://onco.cc/trials/nct04133636/), [A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma](https://onco.cc/trials/nct07266441/), [A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma.](https://onco.cc/trials/nct06232096/), [A Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma](https://onco.cc/trials/nct02963493/), [A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide](https://onco.cc/trials/nct03151811/), [A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant](https://onco.cc/trials/nct06679829/), [A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma](https://onco.cc/trials/nct07116616/), [A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Multiple Myeloma](https://onco.cc/trials/nct00434161/), [A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refrac](https://onco.cc/trials/nct04414475/), [A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal](https://onco.cc/trials/nct05552222/), [A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma](https://onco.cc/trials/nct04586426/), [A Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma (AMMADINA)](https://onco.cc/trials/nct07742215/), [A Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma](https://onco.cc/trials/nct03933735/), [A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma](https://onco.cc/trials/nct06115135/), [A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lena](https://onco.cc/trials/nct07095452/), [A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma ](https://onco.cc/trials/nct06953960/), [A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-spe](https://onco.cc/trials/nct06892522/), [A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Mult](https://onco.cc/trials/nct06669247/), [A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly](https://onco.cc/trials/nct05827016/), [A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)](https://onco.cc/trials/nct07393282/), [A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone](https://onco.cc/trials/nct06952478/), [A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)](https://onco.cc/trials/quintessential-2/), [A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alo](https://onco.cc/trials/nct06045806/), [A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple](https://onco.cc/trials/nct02773030/), [A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Tre](https://onco.cc/trials/nct03989414/), [A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatama](https://onco.cc/trials/nct06988488/), [A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel](https://onco.cc/trials/nct07149857/), [A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants W](https://onco.cc/trials/nct05552976/), [A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Re](https://onco.cc/trials/nct05519085/), [A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events](https://onco.cc/trials/nct06500884/), [A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed ](https://onco.cc/trials/nct05372354/), [A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Mult](https://onco.cc/trials/nct07227311/), [A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma](https://onco.cc/trials/nct07284758/), [A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant](https://onco.cc/trials/nct07297329/), [A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory](https://onco.cc/trials/nct05704049/), [A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatme](https://onco.cc/trials/nct05714839/), [A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide](https://onco.cc/trials/nct05623020/), [A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments](https://onco.cc/trials/nct05020236/), [A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Re](https://onco.cc/trials/nct05730036/), [A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma](https://onco.cc/trials/nct07455851/), [A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnose](https://onco.cc/trials/nct05828511/), [Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies](https://onco.cc/trials/nct07523555/), [AE-941 in Treating Patients With Relapsed or Refractory Multiple Myeloma](https://onco.cc/trials/nct00022282/), [All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myelo](https://onco.cc/trials/nct06956170/), [An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial](https://onco.cc/trials/nct03844048/), [An Open-Label Clinical Study of the Efficacy and Safety of BCD-248 in Patients With Relapsed/Refractory Multiple Myeloma](https://onco.cc/trials/nct06668792/), [Aplidin - Dexamethasone in Relapsed/Refractory Myeloma](https://onco.cc/trials/nct01102426/), [AQUILA](https://onco.cc/trials/aquila/), [AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)](https://onco.cc/trials/nct05850234/), [AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma](https://onco.cc/trials/nct06106945/), [BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease](https://onco.cc/trials/nct04271644/), [CARTITUDE-1](https://onco.cc/trials/cartitude-1/), [CARTITUDE-4](https://onco.cc/trials/cartitude-4/), [CARTITUDE-5](https://onco.cc/trials/cartitude-5/), [CARTITUDE-6](https://onco.cc/trials/cartitude-6/), [CASSIOPEIA](https://onco.cc/trials/cassiopeia/), [CEPHEUS](https://onco.cc/trials/cepheus/), [Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma](https://onco.cc/trials/nct07555938/), [China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexame](https://onco.cc/trials/nct06868654/), [Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)](https://onco.cc/trials/nct03915184/), [Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide](https://onco.cc/trials/nct00083382/), [Comparison of Ibandronate - Zoledronate Regarding Nephrotoxicity in Multiple Myeloma](https://onco.cc/trials/nct02739594/), [DETERMINATION](https://onco.cc/trials/determination/), [Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma](https://onco.cc/trials/nct00033332/), [DRAMMATIC](https://onco.cc/trials/drammatic/), [DREAMM-7](https://onco.cc/trials/dreamm-7/), [DREAMM-8](https://onco.cc/trials/dreamm-8/), [Emapalumab Prophylaxis of Bispecific T-Cell Engagers (BiTEs) Associated CRS and ICANS](https://onco.cc/trials/nct07567014/), [Filgrastim With or Without Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide](https://onco.cc/trials/nct01301963/), [FUMANBA-1](https://onco.cc/trials/fumanba-1/), [Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study](https://onco.cc/trials/nct06052826/), [GR1803 Injection in Patients With Relapsed/Refractory Multiple Myeloma](https://onco.cc/trials/nct06566547/), [HBI0101 (NXC-201) multiple myeloma phase 1](https://onco.cc/trials/nxc-201-mm/), [Human BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM](https://onco.cc/trials/nct05594797/), [IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers](https://onco.cc/trials/nct06119685/), [IFM 2009](https://onco.cc/trials/ifm-2009/), [iMMagine-1](https://onco.cc/trials/immagine-1/), [IMROZ](https://onco.cc/trials/imroz/), [Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma](https://onco.cc/trials/nct04270409/), [iStopMM](https://onco.cc/trials/istopmm/), [Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dex](https://onco.cc/trials/nct06868667/), [KarMMa-3](https://onco.cc/trials/karmma-3/), [LEGEND-2](https://onco.cc/trials/legend-2/), [LINKER-MM1](https://onco.cc/trials/linker-mm1/), [LUMMICAR STUDY 1](https://onco.cc/trials/lummicar-1/), [MagnetisMM-3](https://onco.cc/trials/magnetismm-3/), [MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other](https://onco.cc/trials/nct06152575/), [MAIA](https://onco.cc/trials/maia/), [MajesTEC-1](https://onco.cc/trials/majestec-1/), [MajesTEC-3](https://onco.cc/trials/majestec-3/), [Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance](https://onco.cc/trials/nct06483100/), [Mobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma Patients](https://onco.cc/trials/nct00103662/), [Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients](https://onco.cc/trials/nct06514508/), [MonumenTAL-1](https://onco.cc/trials/monumental-1/), [NHS-Galleri](https://onco.cc/trials/nhs-galleri/), [Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants ](https://onco.cc/trials/nct04975997/), [Pamidronate Prophylaxis in Multiple Myeloma 30 mg/Month Versus 90 mg/Month](https://onco.cc/trials/nct00376883/), [PERSEUS](https://onco.cc/trials/perseus/), [Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma](https://onco.cc/trials/nct07018050/), [Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple](https://onco.cc/trials/nct04126200/), [Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma](https://onco.cc/trials/nct06484829/), [Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma](https://onco.cc/trials/nct05565807/), [Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)](https://onco.cc/trials/nct06087653/), [SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer](https://onco.cc/trials/nct04977024/), [Selinexor and Backbone Treatments of Multiple Myeloma Patients](https://onco.cc/trials/nct02343042/), [Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis](https://onco.cc/trials/nct03315026/), [Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refracto](https://onco.cc/trials/nct06158841/), [Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma](https://onco.cc/trials/nct06297226/), [Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT](https://onco.cc/trials/nct07764978/), [Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom](https://onco.cc/trials/nct02952508/), [Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)](https://onco.cc/trials/nct05862012/), [Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma](https://onco.cc/trials/nct04649060/), [Study of ODX (OsteoDex) in Multiple Myeloma](https://onco.cc/trials/nct06616389/), [Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma](https://onco.cc/trials/nct04782687/), [Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple](https://onco.cc/trials/nct04162210/), [Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)](https://onco.cc/trials/nct02899052/), [Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma](https://onco.cc/trials/nct04879043/), [Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies](https://onco.cc/trials/nct04068597/), [Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant](https://onco.cc/trials/nct05317416/), [Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants Wi](https://onco.cc/trials/nct07150104/), [Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM](https://onco.cc/trials/nct07217119/), [Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM](https://onco.cc/trials/nct07217184/), [Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM](https://onco.cc/trials/nct07084896/), [Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM](https://onco.cc/trials/nct07150091/), [To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma](https://onco.cc/trials/nct07454187/)
- people: [A. Keith Stewart](https://onco.cc/people/keith-stewart/), [Ajai Chari](https://onco.cc/people/ajai-chari/), [Akifumi Takaori](https://onco.cc/people/akifumi-takaori/), [Benjamin L. Ebert](https://onco.cc/people/benjamin-ebert/), [C. Ola Landgren](https://onco.cc/people/ola-landgren/), [Graham H. Jackson](https://onco.cc/people/graham-jackson/), [Jesús G. Berdeja](https://onco.cc/people/jesus-berdeja/), [Jesús San Miguel](https://onco.cc/people/jesus-san-miguel/), [Joaquín Martínez-López](https://onco.cc/people/joaquin-martinez-lopez/), [John F. DiPersio](https://onco.cc/people/john-dipersio/), [Julian Adams](https://onco.cc/people/julian-adams/), [Jürgen Kuball](https://onco.cc/people/jurgen-kuball/), [Kenneth C. Anderson](https://onco.cc/people/kenneth-anderson/), [María-Victoria Mateos](https://onco.cc/people/maria-victoria-mateos/), [Martin Bornhäuser](https://onco.cc/people/martin-bornhauser/), [Meletios A. Dimopoulos](https://onco.cc/people/meletios-dimopoulos/), [Michel Attal](https://onco.cc/people/michel-attal/), [Nicolaas P.M. Schaap](https://onco.cc/people/nicolaas-schaap/), [Nikhil C. Munshi](https://onco.cc/people/nikhil-munshi/), [Noopur Raje](https://onco.cc/people/noopur-raje/), [Paul G. Richardson](https://onco.cc/people/paul-richardson/), [Philippe Moreau](https://onco.cc/people/philippe-moreau/), [Pieter Sonneveld](https://onco.cc/people/pieter-sonneveld/), [Ralf C. Bargou](https://onco.cc/people/ralf-c-bargou/), [S. Vincent Rajkumar](https://onco.cc/people/vincent-rajkumar/), [Saad Z. Usmani](https://onco.cc/people/saad-usmani/), [Sagar Lonial](https://onco.cc/people/sagar-lonial/), [Shaji K. Kumar](https://onco.cc/people/shaji-kumar/), [Sigurdur Y. Kristinsson](https://onco.cc/people/sigurdur-kristinsson/), [Sundar Jagannath](https://onco.cc/people/sundar-jagannath/), [Thierry Facon](https://onco.cc/people/thierry-facon/), [Zonghai Li](https://onco.cc/people/li-zonghai/)
- journals: [Blood cancer discovery](https://onco.cc/journals/blood-cancer-discovery/), [Blood cancer journal](https://onco.cc/journals/blood-cancer-journal/), [Clinical lymphoma, myeloma & leukemia](https://onco.cc/journals/clinical-lymphoma-myeloma-and-leukemia/), [Current hematologic malignancy reports](https://onco.cc/journals/current-hematologic-malignancy-reports/), [Haematologica](https://onco.cc/journals/haematologica/), [Journal of hematology & oncology](https://onco.cc/journals/journal-of-hematology-and-oncology/), [Leukemia & lymphoma](https://onco.cc/journals/leukemia-and-lymphoma/)
- ideas: [A prevention programme for chemotherapy nerve damage: SARM1 inhibitors, cooling and compression](https://onco.cc/ideas/idea-moon-neuropathy-prevention-programme/), [A watch-and-wait registry for blood precursor conditions found by chance](https://onco.cc/ideas/idea-prev-blood-precursor-watch-registry/), [Collect and freeze T cells at diagnosis for high-risk patients, before chemotherapy](https://onco.cc/ideas/idea-reg-early-apheresis-banking/), [Fix the neutrophil count rule that excludes many people of African ancestry](https://onco.cc/ideas/idea-tr1-duffy-null-neutrophil-threshold/), [Harmonise Europe's hospital exemption for academic cell therapies, with one registry](https://onco.cc/ideas/idea-reg-hospital-exemption-harmonised/), [Hospital-based CAR-T manufacturing at cost through a public network](https://onco.cc/ideas/idea-fund-public-car-t-manufacturing/), [Hospital-made CAR-T under one shared regulatory master file](https://onco.cc/ideas/idea-reg-point-of-care-cart-network/), [In vivo CAR-T manufactured and priced like a generic biologic](https://onco.cc/ideas/idea-moon-in-vivo-cart-generic-price/), [Kidney and liver impairment dosing studies completed before approval, not years after](https://onco.cc/ideas/idea-tr1-organ-impairment-pk-before-approval/), [Milestone-based venture philanthropy with royalties recycled into the pipeline](https://onco.cc/ideas/idea-fund-milestone-venture-philanthropy/), [MRD-guided treatment-free intervals in myeloma](https://onco.cc/ideas/idea-mrd-guided-stop-myeloma/), [One CAR-T infusion instead of autologous transplant](https://onco.cc/ideas/idea-car-t-replaces-transplant/), [Outcome-based annuity payments for potentially curative one-time therapies](https://onco.cc/ideas/idea-fund-pay-for-cure-annuities/), [Plan the second CAR-T target before the first one is lost](https://onco.cc/ideas/idea-bio1-adaptive-car-antigen-switch/), [Rapid diagnostic centres for people with vague but worrying symptoms](https://onco.cc/ideas/idea-acc-rapid-diagnostic-centres-vague-symptoms/), [Reduce the dose once the cancer responds: response-adapted de-escalation trials](https://onco.cc/ideas/idea-tr1-response-adapted-dose-reduction/), [Replace fixed kidney and liver cut-offs with drug-specific, pharmacology-based thresholds](https://onco.cc/ideas/idea-tr1-pk-informed-organ-thresholds/)
- pathways: [B-cell receptor / BTK signalling (to NF-κB)](https://onco.cc/pathways/bcr-signalling/), [Complement in cancer](https://onco.cc/pathways/complement-in-cancer/), [Ubiquitin-proteasome system & protein homeostasis](https://onco.cc/pathways/ubiquitin-proteasome-system/)
- bottlenecks: [Dormant cells and minimal residual disease](https://onco.cc/bottlenecks/b-dormancy-mrd/), [Incentives reward me-too drugs and marginal gains](https://onco.cc/bottlenecks/b-incentive-misalignment/), [Manufacturing cost and time for living and radioactive medicines](https://onco.cc/bottlenecks/b-manufacturing-cell-therapy/), [Older and multimorbid patients are excluded and undertreated](https://onco.cc/bottlenecks/b-aging-comorbidity/), [Trial design, endpoints and cost](https://onco.cc/bottlenecks/b-trial-design/), [Trials do not represent the people who get cancer](https://onco.cc/bottlenecks/b-trial-diversity/)
- key papers: [CARTITUDE-1: cilta-cel, a BCMA CAR-T, in heavily pretreated myeloma](https://onco.cc/key-papers/paper-cartitude-1-cilta-cel-lancet-2021/), [CARTITUDE-4: cilta-cel CAR-T versus standard combinations after one to three prior lines of myeloma therapy](https://onco.cc/key-papers/paper-cartitude-4-cilta-cel-nejm-2023/), [CEPHEUS: daratumumab quadruplet for newly diagnosed myeloma patients not having a transplant, with MRD-negativity as the main endpoint](https://onco.cc/key-papers/paper-cepheus-dara-vrd-natmed-2025/), [Development and manufacture of novel locally produced anti-BCMA CAR T cells for the treatment of relapsed/refractory multiple myeloma: results from a phase I clinical trial (HBI0101)](https://onco.cc/key-papers/paper-nxc-201-hbi0101-asherie-haematologica-2023/), [IARC verdict: excess body fat causes 13 cancers](https://onco.cc/key-papers/paper-body-fatness-iarc-nejm-2016/), [KarMMa-3: ide-cel CAR-T versus standard regimens in triple-class-exposed relapsed myeloma](https://onco.cc/key-papers/paper-karmma-3-ide-cel-nejm-2023/), [MagnetisMM-3: elranatamab, a second BCMA bispecific, with a switch to fortnightly dosing after response](https://onco.cc/key-papers/paper-magnetismm-3-elranatamab-natmed-2023/), [MAIA: adding daratumumab to lenalidomide-dexamethasone for older patients with newly diagnosed myeloma who cannot have a transplant](https://onco.cc/key-papers/paper-maia-daratumumab-rd-nejm-2019/), [MajesTEC-1: teclistamab, an off-the-shelf BCMA bispecific antibody, in heavily pretreated myeloma](https://onco.cc/key-papers/paper-majestec-1-teclistamab-nejm-2022/), [Performance of a multi-cancer early detection test in the randomized controlled NHS-Galleri trial](https://onco.cc/key-papers/paper-nhs-galleri-performance-nat-med-2026/), [PERSEUS: daratumumab added to bortezomib-lenalidomide-dexamethasone around autologous transplant in newly diagnosed myeloma](https://onco.cc/key-papers/paper-perseus-dara-vrd-transplant-nejm-2024/)
- biomarkers: [BCMA expression](https://onco.cc/biomarkers/bcma-expression/), [CD38 expression](https://onco.cc/biomarkers/cd38-expression/), [FcRH5 expression](https://onco.cc/biomarkers/fcrh5-expression/), [GPRC5D expression](https://onco.cc/biomarkers/gprc5d-expression/)
- cancers: [Newly diagnosed multiple myeloma, transplant-eligible](https://onco.cc/cancers/myeloma-transplant-eligible/), [Newly diagnosed multiple myeloma, transplant-ineligible](https://onco.cc/cancers/myeloma-transplant-ineligible/), [Plasma cell leukaemia](https://onco.cc/cancers/plasma-cell-leukaemia/), [Relapsed or refractory multiple myeloma](https://onco.cc/cancers/myeloma-relapsed-refractory/), [Smouldering multiple myeloma](https://onco.cc/cancers/smouldering-myeloma/)

---
JSON: https://onco.cc/api/v1/entities/multiple-myeloma.json